[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577010":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":73,"collaborators":30,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":30,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":30,"enrollmentInfo":84,"targetDuration":30,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":30,"overallStatus":38,"whyStopped":30,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Bantam Pharmaceuticals","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BTM-3566 Treatment","EXPERIMENTAL","BTM-3566 Oral Solution",[13],"Drug: BTM-3566",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","BTM-3566","Oral Solution",[9],[11],[22],{"name":23,"affiliation":5,"role":24},"Glen Weiss, MD","STUDY_DIRECTOR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Lori McDermott","CONTACT","1-646-598-4823",null,"lmcdermott@bantampharma.com",{"name":33,"role":28,"phone":30,"phoneExt":30,"email":34},"Meghan Reynolds","mreynolds@bantampharma.com",[36,58],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Levine Cancer Institute, Atrium Health","RECRUITING","Charlotte","North Carolina","28204","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-80.84313,35.22709,{"lat":48,"lon":47},[51,55],{"name":52,"role":28,"phone":53,"phoneExt":30,"email":54},"Phase 1 Oncology Research Nurse","800-804-9376","Alexandra.M.White@advocatehealth.org",{"name":56,"role":57,"phone":30,"phoneExt":30,"email":30},"Steven Park","PRINCIPAL_INVESTIGATOR",{"facility":59,"status":38,"city":60,"state":61,"zip":62,"country":42,"countryCode":43,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":45,"coordinates":64},[65,66],-95.36327,29.76328,{"lat":66,"lon":65},[69,72],{"name":70,"role":28,"phone":71,"phoneExt":30,"email":30},"Luhua M Wang, MD","713-792-2121",{"name":70,"role":57,"phone":30,"phoneExt":30,"email":30},{"type":74,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100577010","phase-1-phase-1-trial-of-btm-3566-in-relapsedrefractory-mature-b-cell-lymphomas-100577010",false,"NCT06792734","Phase 1 Trial of BTM-3566 in Relapsed\u002FRefractory Mature B Cell Lymphomas","Phase 1A\u002F1B Trial of BTM-3566 in Relapsed\u002FRefractory Mature B Cell Lymphomas","Inclusion Criteria:\n\n* must be age ≥18 years\n* must have a diagnosis of relapsed or refractory mature B cell lymphoma\n* must have measurable disease per response evaluation criteria in lymphoma (Lugano classification)\n* must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n* must have a predicted life expectancy of ≥3 months\n* must agree to use adequate birth control throughout their participation and for 90 days following the last dose of BTM-3566\n\nExclusion Criteria:\n\n* has primary CNS lymphoma\n* has ongoing toxicities from prior anti-cancer treatment \\> Grade 1\n* has symptomatic or uncontrolled neurologic disease (brain metastases, leptomeningeal disease, or spinal cord compression) not definitively treated with surgery or radiation\n* has received any anti-cancer therapy (including radiation of curative intent) \\\u003C28 days prior to administration of BTM-3566\n* has current second malignancy at other sites (exceptions: non-melanomatous skin cancer, adequately treated in situ carcinoma, or indolent prostate cancer under observation).\n* is pregnant or breastfeeding","ALL","18 Years",{"count":85,"type":86},24,"ESTIMATED","INTERVENTIONAL",[89],"PHASE1","The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat relapsed or refractory mature b cell lymphomas. The main questions it aims to answer are:\n\nWhat are the side effects of BTM-3566 at different doses? What are the levels of BTM-3566 in the blood at different timepoints around dosing? What is the clinical benefit of BTM-3566 in treating cancer (i.e. how well does it slow or stop disease progression)?\n\nParticipants will:\n\nTake BTM-3566 in 14-day periods with 7 days of dosing followed by 7 days of no dosing Visit the clinic regularly for checkups and tests Keep a diary of their dosing and weight",[92],"Lymphoma, B-Cell","2026-07-03",{"date":95,"type":96},"2026-07-07","ACTUAL",{"date":98,"type":96},"2025-02-14",{"date":100,"type":86},"2027-12",{"name":5,"class":6},2]